CSPC PHARMA (01093) announced that its new chemical entity, a highly selective PDE4B inhibitor (SYH2059 inhalation powder), has received approval from China's National Medical Products Administration to commence clinical trials in China. The product had also previously obtained clearance from the U.S. Food and Drug Administration in March 2026 to proceed with clinical trials in the United States. This innovative product is a novel, highly potent and selective phosphodiesterase-4B (PDE4B) inhibitor with complete independent intellectual property rights owned by the Group. The approved formulation for clinical trials is an inhalation powder. Preclinical studies indicate that the product significantly increases drug concentration in the lungs while reducing systemic exposure, thereby minimizing gastrointestinal side effects. It demonstrated superior efficacy compared to existing treatments in disease animal models, along with favorable pharmacokinetic properties and a high safety margin. The approved clinical indication is for interstitial lung disease. Currently, there are limited treatment options available for this condition, and patient benefits from existing therapies are constrained. This product holds potential as an effective treatment for this disease category, representing significant clinical development value. The clinical trial approval marks a major achievement for the Group's advanced innovative inhalation technology platform and establishes a solid foundation for the development of subsequent innovative inhalation formulations within its pipeline.
Comments